Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1741-1750

  Leal, Alexis D ^a   Thompson, Carrie A ^a   Wang, Alice H ^a   Vierkant, Robert A ^a   Habermann, Thomas M ^a   Ross, Julie A ^b   Mesa, Ruben A ^c   Virnig, Beth A ^b   Cerhan, James R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

essential thrombocythemia; lifestyle; myeloproliferative neoplasm; polycythemia vera; risk factor

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CANCER RISK; COHORT ANALYSIS; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHYSICAL ACTIVITY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; THROMBOCYTHEMIA;

ESSENTIAL THROMBOCYTHEMIA; LIFESTYLE; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTHROPOMETRY; BODY MASS INDEX; FEMALE; HUMANS; IOWA; LIFE STYLE; MOTOR ACTIVITY; MYELOPROLIFERATIVE DISORDERS; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; WOMEN'S HEALTH;

EID: 84892612635     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28492     Document Type: Article

References (40)

1. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-8.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.
3. Chaiter Y, Brenner B, Aghai E, et al. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992; 7: 251-5.
4. Najean Y, Rain JD, Billotey C,. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998; 40: 159-65.
5. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-204.
6. Giles GG, Lickiss JN, Baikie MJ, et al. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst 1984; 72: 1233-40.
7. Hemminki K, Jiang Y,. Familial polycythemia vera: results from the Swedish Family-Cancer Database. Leukemia 2001; 15: 1313-5.
8. Zoloth SR, Michaels DM, Villalbi JR, et al. Patterns of mortality among commercial pressmen. J Natl Cancer Inst 1986; 76: 1047-51.
9. Mele A, Visani G, Pulsoni A, et al. Risk factors for essential thrombocythemia: a case-control study. Italian Leukemia Study Group. Cancer 1996; 77: 2157-61.
10. Kroll ME, Murphy F, Pirie K, et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer 2012; 107: 879-87.
11. Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216-20.
12. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822-8.
13. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000; 160: 2117-28.
14. Bisgard KM, Folsom AR, Hong CP, et al. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 1994; 139: 990-1000.
15. Virnig B, Durham SB, Folsom AR, et al. Linking the Iowa Women's Health Study cohort to Medicare data: linkage results and application to hip fracture. Am J Epidemiol 2010; 172: 327-33.
16. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-48.
17. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008; 83: 359-62.
18. Cox DR,. Regression models and life tables [with discussion]. J R Stat Soc B 1972; 34: 187-220.
19. Korn EL, Graubard BI, Midthune D,. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997; 145: 72-80.
20. Lunn M, McNeil D,. Applying Cox regression to competing risks. Biometrics 1995; 51: 524-32.
21. Murphy F, Kroll ME, Reeves G, et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer 2013; 108: 2390-8.
22. Ross JA, Parker E, Blair CK, et al. Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1810-3.
23. Saberi Hosnijeh F, Romieu I, Gallo V, et al. Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2013; 24: 427-38.
24. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 2005; 97: 1154-7.
25. Pasqualetti P, Casale R, Colantonio D, et al. Occupational risk for hematological malignancies. Am J Hematol 1991; 38: 147-9.
26. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
27. Ross JA, Blair CK, Cerhan JR, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2011; 20: 1741-50.
28. Kasum CM, Blair CK, Folsom AR, et al. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 2003; 12: 534-7.
29. Walter RB, Milano F, Brasky TM, et al. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 2011; 29: 2424-31.
30. Hasselbalch HC,. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219-25.
31. Hasselbalch HC,. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013; 37: 214-20.
32. Hursting SD, Hursting MJ,. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 2012; 32: 1766-70.
33. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-51.
34. Tsujii M, DuBois RN,. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
35. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-45.
36. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
37. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
38. Thun MJ, Henley SJ, Patrono C,. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
39. Hecht SS,. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012; 131: 2724-32.
40. Selinger HA, Ma X,. Jakking up tumor registry reporting of the myeloproliferative neoplasms. Am J Hematol 2009; 84: 124-6.